New pill targets rare genetic cancers in first human trial
NCT ID NCT05653869
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-stage study tests an experimental oral drug, APS03118, in adults with advanced solid tumors that have specific RET gene mutations or fusions. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 108 participants will take the pill by mouth, and researchers will monitor side effects and any anti-cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RET-ALTERED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Conditions
Explore the condition pages connected to this study.